Clinical Trials · NCT05894239

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Name: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Hoffmann-La Roche
Enrollment: 230
Start date: Sep 2023
Locations: 192 sites, 29 countries
Primary endpoint: Investigator-Assessed Progression-Free Survival (PFS)

View Gonadorelin compound reference